ABELCET Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Abelcet patents expire, and what generic alternatives are available?
Abelcet is a drug marketed by Leadiant Biosci Inc and is included in one NDA.
The generic ingredient in ABELCET is amphotericin b. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Abelcet
A generic version of ABELCET was approved as amphotericin b by XGEN PHARMS on April 29th, 1992.
Summary for ABELCET
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 61 |
| Clinical Trials: | 3 |
| Patent Applications: | 7,317 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ABELCET |
| What excipients (inactive ingredients) are in ABELCET? | ABELCET excipients list |
| DailyMed Link: | ABELCET at DailyMed |
Recent Clinical Trials for ABELCET
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ministry of Health, Spain | Phase 2 |
| Fundació Sant Joan de Déu | Phase 2 |
| University of Pittsburgh | Phase 3 |
Pharmacology for ABELCET
Anatomical Therapeutic Chemical (ATC) Classes for ABELCET
US Patents and Regulatory Information for ABELCET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leadiant Biosci Inc | ABELCET | amphotericin b | INJECTABLE, LIPID COMPLEX;INJECTION | 050724-001 | Nov 20, 1995 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ABELCET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Leadiant Biosci Inc | ABELCET | amphotericin b | INJECTABLE, LIPID COMPLEX;INJECTION | 050724-001 | Nov 20, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Leadiant Biosci Inc | ABELCET | amphotericin b | INJECTABLE, LIPID COMPLEX;INJECTION | 050724-001 | Nov 20, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ABELCET
See the table below for patents covering ABELCET around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 223660 | LOW TOXICITY DRUG-LIPID COMPLEXES; METHODS OF MAKING THEM; AND METHOD OF DETERMINING THEIR TOXICITY | ⤷ Try a Trial |
| Denmark | 98289 | ⤷ Try a Trial | |
| Australia | 1799088 | ⤷ Try a Trial | |
| Norway | 944071 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
